Dario Campana

Active 1981–2024

139
Papers
33,768
Citations
104
h-index
138
i10-index

Citations

Citations per year for Dario Campana1967: 1 citations1984: 1 citations1985: 3 citations1986: 7 citations1987: 9 citations1988: 6 citations1989: 16 citations1990: 18 citations1991: 18 citations1992: 17 citations1993: 30 citations1994: 35 citations1995: 47 citations1996: 56 citations1997: 53 citations1998: 85 citations1999: 75 citations2000: 132 citations2001: 92 citations2002: 144 citations2003: 166 citations2004: 206 citations2005: 170 citations2006: 173 citations2007: 161 citations2008: 221 citations2009: 303 citations2010: 212 citations2011: 263 citations2012: 411 citations2013: 468 citations2014: 349 citations2015: 463 citations2016: 367 citations2017: 400 citations2018: 329 citations2019: 942 citations2020: 1,092 citations2021: 1,080 citations2022: 805 citations2023: 520 citations2024: 791 citations2025: 398 citations2026: 3 citations1968–1983: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,626 citing papers, 30.9% of this breakdownChina: 1,095 citing papers, 9.3% of this breakdownGermany: 811 citing papers, 6.9% of this breakdownUnited Kingdom: 624 citing papers, 5.3% of this breakdownItaly: 556 citing papers, 4.7% of this breakdownFrance: 409 citing papers, 3.5% of this breakdownNetherlands: 396 citing papers, 3.4% of this breakdownCanada: 354 citing papers, 3% of this breakdownAustralia: 315 citing papers, 2.7% of this breakdownJapan: 267 citing papers, 2.3% of this breakdownSpain: 253 citing papers, 2.1% of this breakdownSweden: 223 citing papers, 1.9% of this breakdown
0%30.9%Other 24%

Fields

  • Medicine61.6%
  • Biochemistry, Genetics and Molecular Biology17.9%
  • Immunology and Microbiology16.7%
  • Computer Science1.9%
  • Engineering0.5%
  • Neuroscience0.5%
  • Other0.9%

Topics

  • CAR-T cell therapy research10%
  • Acute Lymphoblastic Leukemia research9.3%
  • Immune Cell Function and Interaction7.5%
  • Acute Myeloid Leukemia Research6%
  • Childhood Cancer Survivors' Quality of Life3.4%
  • T-cell and B-cell Immunology3.1%
  • Other60.7%

Coauthors

All papers

Open in search
  1. NK cells for cancer immunotherapy

    Authors: , , - Nature Reviews Drug Discovery 2020 cited by 1,236

  2. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

    Authors: , , , , , , - Leukemia 2004 cited by 830

  3. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

    Authors: , , , , , , , , , , , , , - Molecular Therapy 2009 cited by 1,189

  4. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cheng Cheng, Stefan Roberts, Michael I. Barbato, Dario Campana, Elaine Coustan‐Smith, Sheila Shurtleff, Susana C. Raimondi, Maria Kleppe, Jan Cools, Kristin A. Shimano, Michelle L. Hermiston, Sergei Doulatov, Kolja Eppert, Elisa Laurenti, Faiyaz Notta, John E. Dick, Giuseppe Basso, Stephen P. Hunger, Mignon L. Loh, Meenakshi Devidas, Brent L. Wood, Stuart S. Winter, Kimberly P. Dunsmore, Robert S. Fulton, Lucinda Fulton, Xin Hong, Christopher Harris, David J. Dooling, Kerri Ochoa, Kimberly Johnson, John C. Obenauer, William E. Evans, Ching‐Hon Pui, Clayton W. Naeve, Timothy J. Ley, Elaine R. Mardis, Richard K. Wilson, James R. Downing, Charles G. Mullighan - Nature 2012 cited by 1,639

  5. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells

    Authors: , , , , - Journal of Clinical Investigation 2019 cited by 340

  6. Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 1,444

  7. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

    Authors: , , , , , , , , , , , , , - The Lancet Oncology 2009 cited by 1,016

  8. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

    Authors: , , - Blood 2005 cited by 657

  9. Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 1,220

  10. A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

    Authors: , , , , , - Cancer Research 2013 cited by 325

  11. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 265

  12. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15

    Authors: , , , , , , , - Blood 2014 cited by 182

  13. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies

    Authors: , , , , , - Blood Advances 2017 cited by 192

  14. Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Discovery 2021 cited by 152

  15. Fratricide-resistant CD7-CAR T cells in T-ALL

    Authors: , , , , , , , , , , , , , , , , , - Nature Medicine 2024 cited by 68

  16. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 67

  17. Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Immunotherapy 2014 cited by 180

  18. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2002 cited by 1,920

  19. Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

    Authors: , , , , , , , , - Cancer Research 2009 cited by 591

  20. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

    Authors: , , , , , , , , , , , , , , , , , , , - Cytotherapy 2012 cited by 208

  21. T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing

    Authors: , , , , , , , - Cancer Research 2013 cited by 207

  22. 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells

    Authors: , , , , , , , , , - Clinical Cancer Research 2009 cited by 204

  23. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2010 cited by 581

  24. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

    Authors: , , , , , , , - Blood 2012 cited by 424